Histone mutations in cancer.
Histone mutations in cancer.
复制标题
DOI：
10.1042/bst20210567
复制
发表时间：
2023-10-31
影响因子：
3.9
通讯作者：
中科院分区：
文献类型：
--
作者：
编码组蛋白的基因在肿瘤样本中反复突变，这些突变可能影响核小体稳定性、组蛋白翻译后修饰或染色质动力学。不同癌症类型中组蛋白突变的普遍存在表明正常染色质结构是肿瘤发生的障碍。癌组蛋白突变破坏染色质结构和基因调控机制，导致基因表达异常和癌症表型的发展。癌组蛋白的例子包括在儿科脑癌中发现的组蛋白 H3 K27M 突变（它阻止 H3 N 末端尾部的翻译后修饰）和在一些实体瘤中发现的组蛋白 H2B E76K 突变（破坏核小体稳定性）。癌组蛋白可能只占总组蛋白池的有限部分，但却对染色质结构产生整体影响并驱动癌症表型。在这里，我们调查了癌症中的组蛋白突变，并回顾了它们在肿瘤发生中的功能和作用。
Genes encoding histone proteins are recurrently mutated in tumor samples, and these mutations may impact nucleosome stability, histone post-translational modification, or chromatin dynamics. The prevalence of histone mutations across diverse cancer types suggest that normal chromatin structure is a barrier to tumorigenesis. Oncohistone mutations disrupt chromatin structure and gene regulatory mechanisms, resulting in aberrant gene expression and the development of cancer phenotypes. Examples of oncohistones include the histone H3 K27M mutation found in pediatric brain cancers that blocks post-translational modification of the H3 N-terminal tail and the histone H2B E76K mutation found in some solid tumors that disrupts nucleosome stability. Oncohistones may comprise a limited fraction of the total histone pool yet cause global effects on chromatin structure and drive cancer phenotypes. Here, we survey histone mutations in cancer and review their function and role in tumorigenesis.
影响因子：
14.9
作者：
Nag R;Gong F;Fahy D;Smerdon MJ
通讯作者：
Smerdon MJ
影响因子：
3.5
作者：
Bacolla A;Cooper DN;Vasquez KM
通讯作者：
Vasquez KM